VG H&N course intro Florence 2016.pptx

Previous Page

Next Page

Page Background

Study

N Regimens

ORR Median

PFS

Median

Survival

Fayette

ESMO LBA 2014 62 59 Cetuximab

versus

MEHD7945A

14.5% 11.9% 4 months

4.1 months 8.5 months

7.2 months

Machiels**

Lancet Oncol

2015

161 322 Methotrexate

versus

Afatinib

5.6% 10.2% 1.7 months

2.6 months* 6 months

6.8 months

* Statistically significant

** Previous used of cetuximab allowed

EGFR/HER3 or pan-HER inhibition